Familial predisposition for psychiatric disorder: Comparison of subjects treated for cannabis-induced psychosis and schizophrenia

Archives of General Psychiatry

Volumn 65, Issue 11, 2008, Pages 1269-1274

  Arendt, Mikkel ^a   Mortensen, Preben B ^b   Rosenberg, Raben ^a   Pedersen, Carsten B ^b   Waltoft, Berit L ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS;

ADOLESCENT; ADULT; ARTICLE; CANNABIS INDUCED PSYCHOSIS; DENMARK; DISEASE PREDISPOSITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; POPULATION RESEARCH; RELATIVE; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA;

ADOLESCENT; ADULT; CANNABINOIDS; COHORT STUDIES; COMORBIDITY; DENMARK; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEALTH SURVEYS; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; ODDS RATIO; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 55749104091     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.65.11.1269     Document Type: Article

References (52)

1. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Geneva, Switzerland: World Health Organization; 1992.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Revision (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
3. Hall W, Degenhardt L. Is there a specific "cannabis psychosis?" In: Castle D, Murray R, eds. Marihuana and Madness. Cambridge, England: Cambridge University Press; 2004:89-100.
4. Boydell J, Dean K, Dutta R, Giouroukou E, Fearon P, Murray R. A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: implications for the concept of cannabis psychosis. Schizophr Res. 2007;93(1-3):203-210.
5. Imade AGT, Ebie JC. A retrospective study of symptom patterns of cannabis-induced psychosis. Acta Psychiatr Scand. 1991;83(2):134-136.
6. Mathers DC, Ghodse AH. Cannabis and psychotic illness. Br J Psychiatry. 1992;161:648-653.
7. McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res. 1995;15(3):277-281.
8. Thornicroft G, Meadows G, Politi P. Is "cannabis psychosis" a distinct category? Eur Psychiatry. 1992;7:277-282.
9. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jørgensen P. Cannabis-induced psychosis and subsequent schizophrenia: follow-up study of 535 incident cases. Br J Psychiatry. 2005;187:510-515.
10. Bersani G, Orlandi V, Kotzalidis GD, Pancheri P. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci. 2002;252(2):86-92.
11. Pedersen CB, Gøtzsche H, Møller JØ, Mortensen PB. The Danish Civil Registration System. Dan Med Bull. 2006;53(4):441-449.
12. Munk-Jørgensen P, Mortensen P. The Danish Psychiatric Central Register. Dan Med Bull. 1997;44(1):82-84.
13. World Health Organization. Classification of Diseases: Extended Danish-Latin Version of the World Health Organization International Classification of Diseases. 8th Rev. 1965. Copenhagen, Denmark: Danish National Board of Health; 1971.
14. Breslow NE, Day NE. Statistical methods in cancer research, II: the design and analysis of cohort studies. IARC Sci Publ. 1987;(82):1-406.
15. Pierce DA, Preston DL. Joint analysis of site-specific cancer risks for the atomic bomb survivors. Radiat Res. 1993;134(2):134-142.
16. SAS Institute, Inc. The GENMOD Procedure. SAS/STAT 9.1 User's Guide. Cary, NC: SAS Institute, Inc; 2004:1609-1730.
17. Clayton D, Hills M. Statistical Models in Epidemiology. New York, NY: Oxford University Press; 1993.
18. Rosthøj S, Andersen PK, Abildstrom SZ. SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data. Comput Methods Programs Biomed. 2004;74(1):69-75.
19. Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry. 1970;126(7):983-987.
20. Poole R, Brabbins C. Drug induced psychosis. Br J Psychiatry. 1996;168(2):135-138.
21. Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry. 1993;163:141-149.
22. Bühler B, Hambrecht M, Loffler W, an der Heiden W, Häfner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse: a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res. 2002;54(3):243-251.
23. Compton MT, Furman AC, Kaslow NJ. Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. Schizophr Res. 2004;71(1):61-64.
24. Soyka M, Albus M, Immler B, Kathmann N, Hippius H. Psychopathology in dual diagnosis and non-addicted schizophrenics: are there differences? Eur Arch Psychiatry Clin Neurosci. 2001;251(5):232-238.
25. Mortensen PB, Eaton WW. Predictors for readmission risk in schizophrenia. Psychol Med. 1994;24(1):223-232.
26. Basu D, Malhotra A, Bhagat A, Varma VK. Cannabis psychosis and acute schizophrenia. a case-control study from India. Eur Addict Res. 1999;5(2):71-73.
27. Chaudry HR, Moss HB, Bashir A, Suliman T. Cannabis psychosis following bhang ingestion. Br J Addict. 1991;86(9):1075-1081.
28. Kolansky H, Moore WT. Effects of marihuana on adolescents and young adults. JAMA. 1971;216(3):486-492.
29. Núñez LA, Gurpegui M. Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatr Scand. 2002;105(3):173-178.
30. Pålsson A, Thulin O, Tunving K. Cannabis psychoses in South Sweden. Acta Psychiatr Scand. 1982;66(4):311-321.
31. Rolfe M, Tang CM, Sabally S, Todd JE, Sam EB, Hatib N'Jie AB. Psychosis and cannabis abuse in The Gambia: a case-control study. Br J Psychiatry. 1993;163:798-801.
32. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212-1213.
33. Fergusson DM, Poulton R, Smith PF, Boden JM. Cannabis and psychosis. BMJ. 2006;332(7534):172-175.
34. Hall W. Is cannabis use psychotogenic? Lancet. 2006;367(9506):193-195.
35. Andréasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet. 1987;2(8574):1483-1486.
36. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med. 2003;33(1):15-21.
37. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ. 2005;330(7481):11-16.
38. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction. 2004;99(10):1333-1341.
39. van Os J, Bak M, Hanssen M, Bijl RV, de Graff R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156(4):319-327.
40. Weiser M, Knobler HY, Noy S, Kaplan Z. Clinical characteristics of adolescents later hospitalized for schizophrenia. Am J Med Genet. 2002;114(8):949-955.
41. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325(7374):1199-1204.
42. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319-328.
43. Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Davey Smith G. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet. 2004;363(9421):1579- 1588.
44. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M, Ramaekers JG, van Os J. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology. 2006;31(12):2748-2757.
45. Verdoux H. Cannabis and psychosis proneness. In: Castle D, Murray R, eds. Marihuana and Madness. Cambridge, England: Cambridge University Press; 2004:75-88.
46. Castle DJ, Solowij N. Acute and subacute psychotomimetic effects of cannabis use in humans. In: Castle D, Murray R, eds. Marihuana and Madness. Cambridge, England: Cambridge University Press; 2004:89-100.
47. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguiva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594-608.
48. Reilly D, Didcott P, Swift W, Hall W. Long-term cannabis use: characteristics of users in an Australian rural area. Addiction. 1998;93(6):837-846.
49. Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend. 1996;42(3):201-207.
50. Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323(7303):16-21.
51. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The State of Drugs Problem in Europe: Annual Report. Luxemburg, Belgium: Office for Official Publications of the European Communities; 2007.
52. Mechoulam R, Hanus L. The cannabinoid system: from the point of view of a chemist. In: Castle D, Murray R, eds. Marihuana and Madness. Cambridge, England: Cambridge University Press; 2004:1-18.